Skip to content

Study · Animal study (in vivo) · cat · 2016

5 results

Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus.

Riederer A, Zini E, Salesov E, Fracassi F, Padrutt I, Macha K, Stöckle TM, Lutz TA, Reusch CE

Journal of veterinary internal medicine24 Dec 2015Cited by 26 (Europe PMC)

PMID26700409 (opens in a new tab)PMCIDPMC4913624 (opens in a new tab)DOI10.1111/jvim.13817 (opens in a new tab)PepBankPUB-26700409
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In diabetic cats, decreased appetite occurred in 60% with exenatide ER versus 20% with placebo, without statistical significance.

    In plain wordsIn cats with diabetes, decreased appetite occurred in 60% with exenatide ER versus 20% with placebo, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDecreased appetite
    Study

    catn = 30

    newly diagnosed diabetes mellitus
    Comparator
    placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 16 weeks, or 4 weeks after insulin discontinuation in cats achieving remissionAs given in this study (cat).

    Source sentences

    Summary
    Cats in the exenatide ER and placebo groups had transient adverse signs including decreased appetite (60% vs. 20%, respectively, P = .06) and vomiting (53% vs. 40%, respectively, P = .715).
    4 context sentences
    Summary · context
    Prospective placebo-controlled clinical trial.
    Summary · context
    Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly.
    Summary · context
    Both groups received insulin glargine and a low-carbohydrate diet.
    Summary · context
    Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In diabetic cats, vomiting occurred in 53% with exenatide ER versus 40% with placebo, without statistical significance.

    In plain wordsIn cats with diabetes, vomiting occurred in 53% with exenatide ER versus 40% with placebo, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeVomiting
    Study

    catn = 30

    newly diagnosed diabetes mellitus
    Comparator
    placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 16 weeks, or 4 weeks after insulin discontinuation in cats achieving remissionAs given in this study (cat).

    Source sentences

    Summary
    Cats in the exenatide ER and placebo groups had transient adverse signs including decreased appetite (60% vs. 20%, respectively, P = .06) and vomiting (53% vs. 40%, respectively, P = .715).
    4 context sentences
    Summary · context
    Prospective placebo-controlled clinical trial.
    Summary · context
    Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly.
    Summary · context
    Both groups received insulin glargine and a low-carbohydrate diet.
    Summary · context
    Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic cats, remission occurred in 40% with exenatide ER versus 20% with placebo, without a significant difference.

    In plain wordsIn cats with diabetes, remission occurred in 40% with exenatide ER versus 20% with placebo, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDiabetes remission
    Study

    catn = 30

    newly diagnosed diabetes mellitus
    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 16 weeks, or 4 weeks after insulin discontinuation in cats achieving remissionAs given in this study (cat).

    Source sentences

    Summary
    Cats on exenatide ER achieved remission or good metabolic control in 40% or 89%, respectively, whereas in control cats percentages were 20% or 58% (P = .427 and P = .178, respectively).
    4 context sentences
    Summary · context
    Prospective placebo-controlled clinical trial.
    Summary · context
    Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly.
    Summary · context
    Both groups received insulin glargine and a low-carbohydrate diet.
    Summary · context
    Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic cats, good metabolic control occurred in 89% with exenatide ER versus 58% with placebo, without a significant difference.

    In plain wordsIn cats with diabetes, good metabolic control occurred in 89% with exenatide ER versus 58% with placebo, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGood metabolic control
    Study

    catn = 30

    newly diagnosed diabetes mellitus
    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 16 weeks, or 4 weeks after insulin discontinuation in cats achieving remissionAs given in this study (cat).

    Source sentences

    Summary
    Cats on exenatide ER achieved remission or good metabolic control in 40% or 89%, respectively, whereas in control cats percentages were 20% or 58% (P = .427 and P = .178, respectively).
    4 context sentences
    Summary · context
    Prospective placebo-controlled clinical trial.
    Summary · context
    Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly.
    Summary · context
    Both groups received insulin glargine and a low-carbohydrate diet.
    Summary · context
    Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic cats receiving exenatide ER, body weight did not increase significantly.

    In plain wordsIn cats with diabetes receiving exenatide ER, body weight did not increase significantly.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBody weight
    Study

    catn: not reported in source

    newly diagnosed diabetes mellitus
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 16 weeks, or 4 weeks after insulin discontinuation in cats achieving remissionAs given in this study (cat).

    Source sentences

    Summary
    Body weight increased significantly in the placebo group (P = .002), but not in cats receiving exenatide ER.
    4 context sentences
    Summary · context
    Prospective placebo-controlled clinical trial.
    Summary · context
    Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly.
    Summary · context
    Both groups received insulin glargine and a low-carbohydrate diet.
    Summary · context
    Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.